Background: Eradication of Helicobacter pylori in gastric mucosa-associated lymphoid tumor can result in lymphoma remission. We prospectively identified/treated infections in nonbulky, advanced stage indolent lymphoma (follicular; nonfollicular lymphoma) eligible for observation. 
introduction
Advanced stage, indolent non-Hodgkin's lymphomas are characterized by long survival, but are incurable with standard therapies. The histological subtypes include follicular lymphoma (FL) grades I, II and IIIA, and nonfollicular lymphoma (nFL) histologies [small lymphocytic lymphoma, lymphoplasmacytoid lymphoma and marginal zone lymphoma (MZL), both nodal and extranodal, i.e. mucosa-associated lymphoid tissue (MALT), types] [1] .
The antigen drive association of gastric MALT lymphoma with Helicobacter pylori is well recognized. Successful antibiotic therapy, to eradicate the H. pylori antigen, can result in lymphoma remission, and with it, lymphoma prevention [2] . We have sought to prospectively identify possible associated infections (candidates for antigen drive) in patients with nonbulky, advanced stage indolent lymphoma as the first step to such a lymphoma treatment/prevention strategy. These patients are often given a recommendation of monitoring ('watch and wait') and it is during this period that a window of opportunity may exist to identify and treat antigen driverelated infections.
The primary objective of this study was to evaluate the possible association of infectious diseases in previously untreated patients with advanced stage, indolent lymphoma, and to assess the incidence of infections identified. The secondary objective was to evaluate possible lymphoma response in patients treated for positive infectious disease.
materials and methods
Patient characteristics are listed in Table 1 infections studied All patients were tested for H. pylori, hepatitis C, Borrelia burgdorferi, Chlamydia psittaci and small bowel bacterial overgrowth. Only the first 13 patients were tested for Borrelia and Chlamydia, as it became evident that these organisms were not present (see Appendix 1).
treatment plan
In those instances where an infection was identified, antibiotics were recommended according to standard guidelines of the Infectious Disease and Gastroenterology Services. Treatment regimens took into consideration the patient's other medical and allergic history. Following specific antibiotic therapy, the patient was reassessed for eradication of the infectious agent by appropriate retesting. In addition to antibiotic response, patients were monitored for lymphoma progression (or regression) according to Memorial SloanKettering Cancer Center (MSKCC) standard guidelines. Response, if any, was measured according to the International Working Group standard response criteria for non-Hodgkin's lymphoma, including complete response (CR), complete response uncertain (CRu) and partial response (PR) [3] .
biostatistics
This was a prospective, hypothesis-generating, exploratory study. Descriptive statistics were utilized to report infection incidence, response to therapy and patient demographics. Time to next lymphoma therapy was measured from enrollment in the study to the date of first lymphoma standard treatment utilizing the method of Kaplan and Meier [4] ; univariate analyses were carried out using the log-rank test [5] . Survival analysis was carried out using SPSS 11.0 (SPSS Inc., Chicago, IL).
results
Infectious diseases detected are shown in Table 2 . Helicobater pylori stool antigen was positive in 13 of 53 patients (24.5%). Hepatitis C antibody was found in three out of 49 patients tested (6.1%): one of 26 FL [genotype 1b and 1 620 000 hepatitis C virus (HCV) IU/ml]; and two of 22 nFL (genotype 1a and >850 000 HCV IU/ml; and genotype 1b and 873 000 HCV IU/ml). HCV status by PCR was not tested in those who were hepatitis C negative. Small bowel bacterial overgrowth was seen in 11 of 54 patients tested (20.4%). Borrelia burgdorferi fixed tissue PCR was negative in 13 of 13 patients tested. Chlamydia was positive in 1 of 13 (8%). In total, 21 of 56 patients had a documented infection (37.5%), five with multiple infections.
Lymphoma treatment responses:
One of 13 patients with H. pylori has achieved CR (FL achieving a PET-negative CR for 24+ months since antibiotics). One patient with cutaneous MZL had a transient near CR (for 5 months). All three patients with hepatitis C have had objective response [one FL with PR for 24+ months, while HCV improved but persistent; two nFL (one CR with MZL for 30+ months; one CRu with MZL for 18+ months)] and in these two patients, HCV has been eradicated. One patient with FL and small bowel bacterial overgrowth (of 11 with positive studies) has had PR for 30+ months after antibiotic therapy.
time to lymphoma treatment
Those patients with associated infections who did not achieve lymphoma CR/CRu to infection treatment (18 patients; nine FL, nine nFL) appear to have required institution of conventional lymphoma therapy significantly sooner than those without initial associated infections (35 patients) (P = 0.01). With 23.4 months median follow-up, the lymphoma treatmentfree survival was 100% for those three patients achieving Figure 1 ).
discussion
Gastric MALT is a well accepted example of antigen drive, in which the B-cell neoplasm evolves by a process of T-cell-driven B-cell proliferation, stimulated by H. pylori. The lymphoproliferative process occurs over many years, and involves a number of steps before the development of an antigen-independent clonal B-cell malignancy [6] . A similar antigen-driven evolution is also hypothesized for follicular lymphomagenesis; however, the antigens involved are unknown [7] . Many investigators have reported that successful eradication of H. pylori with antibiotic therapy can result in resolution of gastric MALT. H. pylori infection has not been associated routinely with other sites of MZL. However, Campylobacter jejuni in small bowel MALT and C. psittaci in orbital MALT [8, 9] have both been reported.
There is an increased association of indolent lymphoma with chronic hepatitis C infection [10] . Antiviral therapy may eradicate hepatitis C infection in some patients [11] , and recent reports document response of both hepatitis C and indolent lymphoma to antiviral therapy alone [12, 13] . Other infectious associations are less well established including cutaneous B-cell lymphoma and B. burgdorferi [14, 15] .
There are no direct data at this time to support the hypothesis that small bowel bacterial overgrowth is a source of antigen drive. However, small intestinal disorders may be associated with indolent lymphoma, including immunoproliferative small intestinal disease, celiac sprue and sprue-like syndromes [16] . Given the causal relationship of H. pylori in gastric MALT, it seems reasonable to hypothesize that other infections and/or bacteria may be a source of antigen drive in this site. Given its inaccessibility, we sought to evaluate the conglomerate surrogate marker of small bowel bacterial overgrowth, postulating that any suggestive finding would allow further tailored investigation into the source of a more specific antigen.
The current study analyzed prospectively the incidence of associated infection in FL and nFL (see Table 2 ). No patients had symptomatic lymphoma or symptomatic infection. Associated infections were found to be frequent in both indolent lymphoma cohorts. Stool H. pylori antigen was identified in 25% of all patients tested, 6% had hepatitis C and 20% of those tested had small bowel bacterial overgrowth. On the other hand, neither Borrelia nor Chlamydia infections were seen, except one patient with C. psittaci (without orbital lymphoma). There were five patients who had more than one infection. All patients were treated for the specific infections identified with a standard course of antibiotics and all have had successful eradication, except for two patients (one with persistent hepatitis C; one with small bowel bacterial overgrowth currently receiving antibiotics).
Although this study's primary aim was to explore possible associated infection and not to assess lymphoma response, we did observe anecdotal responses (see results). Moreover, those patients with associated infections who did not achieve lymphoma CR/CRu to infection treatment appear to have required institution of conventional lymphoma therapy significantly sooner than those without initial associated infections (see Figure 1) . The significance of this observation will require future study, as it may simply be an artifact of patients who were monitored more closely following antibiotics.
We are encouraged by these preliminary data indicating that infections are common in indolent lymphoma (37.5% in our series); and that anecdotal lymphoma responses have been seen, even recognizing that spontaneous regressions are often reported. Three CR/CRu (14.3% of those infected) are ongoing for 18-30+ months with infection eradication alone. Like gastric MALT, it is hoped that these data will support a new clinical paradigm, in which potential sources of antigen drive are identified and eradicated, as the first management option in advanced stage indolent lymphoma not otherwise requiring therapy. In so doing, perhaps this prevention strategy will decrease the risk of future lymphoma progression driven by such antigens. To that end, we recommend that all patients with indolent lymphoma be considered for hepatitis C eradication whenever possible, and we have embarked upon a prospective clinical trial testing the role of prolonged clarithromycin antibiotic therapy as first treatment in hepatitis C-negative patients. The flaB assay were carried out essentially as described by Barbour et al. [17] ospA PCRs were carried out using ospA F 5#-GGGAATAGGTCTAATATTAGCC-3# and ospA 2 5#-TTTCAACTGCTGACCCCTC-3# as forward and reverse primers, respectively, in the first round of PCR, and ospA 4 5#-CTGCAGCTTGGAATTCAGGCACTTC-3# and ospA 2 as forward and reverse primers, respectively in the second round. Dried DNA specimens were suspended in 50 ll of water. PCR were carried out in 25 ll reactions containing 5 ll of DNA and 100 mM (each) deoxynucleoside triphosphates, 1.25 U of Taq DNA polymerase and 20 pmol of each primer in a 'DNA engine' thermocycler (MJ Research, Watertown, MA). For both target genes, second-round PCR was accomplished by transferring 1 ll of the first-round reaction into 24 ll of the second-round master mix. The thermal cycling profile of both first-and secondround PCR consisted of one 3 min cycle at 94°C, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 30 s.
To avoid cross-contamination and sample carryover, pre-and postPCR sample processing and PCR amplification were carried out in separate rooms and all fluid transfers were carried out with plugged pipet tips to eliminate aerosols. Amplified DNA products were detected by agarose gel electrophoresis in Trisborate-EDTA buffer. For any positive PCR specimens, the PCR products were sequenced by automated DNA sequencing. 
